Cardiorenal consequences of atherosclerosis and statins therapy: From the past to the future

Medicine & Life Sciences

• Hydroxymethylglutaryl-CoA Reductase Inhibitors 67%
• Atherosclerosis 55%
• Cardiovascular Diseases 50%
• Peripheral Arterial Disease 38%
• Biomedical Research 34%
• Carotid Arteries 33%
• Incidence 33%
• Vascular Diseases 33%
• Lipid Metabolism 33%
• Developing Countries 31%
• Coronary Vessels 28%
• Cause of Death 27%
• Glucose 21%
• Mortality 17%
• Therapeutics 11%

Chemical Compounds

• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 100%
• Pharmacological Metabolism 53%
• Glucose 50%
• Lipid 47%